The antimalarial drug hydroxychloroquine and the antiviral drugs used to treat the human immunodeficiency virus (HIV), lopinavir and ritonavir, are not efficient in the treatment against Covid-19, stated the World Health Organization (WHO ) in a statement, based on provisional results of the international Solidarity trials.
The international health entity reported that it “today accepted the recommendation of the International Steering Committee for the Solidarity Trial to suspend the hydroxychloroquine and lopinavir / ritonavir arms of the trial”.
"Those provisional trial results show that hydroxychloroquine and lopinavir / ritonavir produce little or no reduction in mortality for hospitalized patients with Covid-19 compared to standard care," he added.
At the same time The WHO assured that "there were some associated safety signs in the clinical laboratory results of trial c Discovery ”, which will be described later in a publication.
The Solidarity trial is an international initiative coordinated by the WHO that aims to compare five treatment options for severe cases of Covid-19: the usual treatment, remdesivir, the antimalarial drug hydroxychloroquine, the HIV drugs ritonavir and / or lopinavir, as well as ritonavir and lopinavir combined with interferon.
On Friday, the organization's director general, Tedros Adhanom Ghebreyesus, indicated that in the trial About 5,500 people in 39 countries are participating, and he indicated that his first results will be available in two weeks.